The United Kingdom and the United States have concluded a landmark bilateral deal that will maintain zero duties on British pharmaceutical exports being sold in the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has pledged to increase spending on pharmaceuticals through the public health system. This commitment secures that import taxes on these crucial products will be held at nothing for a period of the next three years.
This development follows earlier statements to dramatically increase tariffs on branded pharmaceutical imports, with increases mentioned up to 100%.
"This deal between the UK strengthens the international landscape for cutting-edge drugs and establishes much-needed balance to U.S.–U.K. pharmaceutical trade," a release declared.
Economic Importance
Medicines constitute one of the Britain's most significant exports to the US, which is easily the primary buyer for leading UK drugmakers.
Statistics show that in the one-year period prior to September, the UK sold drugs worth over eleven billion pounds to the US. This value made up 17.4% of British export trade in that span.
"This agreement protects employment, stimulates investment and paves the way for the UK to establish itself as a worldwide center for life sciences," a government official stated.
Key UK Commitments
The deal includes several specific changes from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it judges new medicines to be too expensive by a quarter.
- Boosted Medicine Funding: There is a goal to raise total public funding on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Payback Limit: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Previously, repayments topped 20%.
Broader Context
The pact takes place against a ongoing tension between the pharmaceutical industry and the British authorities over medicine costs and approval rates.
These tensions were intensified by arguments that US patients were paying a premium for the same drugs than people in the Britain and the EU.
In recent months, several significant manufacturing plans in the UK have been delayed or scrapped, while substantial investments have been pledged toward American operations.
The Science Minister publicly accepted that the NHS had to invest a greater share on medicines, noting that its spending on drugs had decreased as a share of its resources over the past decade.
